A comparative study of Botulinum toxin type A versus conventional oral therapy as a second-line treatment of diabetic neuropathy

Table 5 Comparison between the different studied periods according to PSQI

PSQI	PSQI 0	PSQI 1 week	PSQI 4 weeks	PSQI 12 weeks	F	p
Duloxetine (n = 10)
Mean ± SD	17.4 ± 2.2	16.7 ± 2.4	15 ± 1.6	13.8 ± 2.4	32.863^*	< 0.001^*
Median (Min.–Max.)	18 (14–20)	17 (14–20)	14.5 (13–18)	13 (9–17)	32.863^*	< 0.001^*
p₁		0.149	0.002^*	< 0.001^*
Gabapentin (n = 10)
Mean ± SD	16.2 ± 2.7	15.7 ± 2.6	14.4 ± 3.2	13.3 ± 3	9.234^*	0.002^*
Median (Min.–Max.)	17.5 (12–19)	16.5 (11–19)	13.5 (9–20)	13.5 (9–19)	9.234^*	0.002^*
p₁		0.313	0.176	0.018^*
Botox (n = 10)
Mean ± SD	17.3 ± 1.8	15.9 ± 2.4	9.9 ± 3.6	10.9 ± 3.1	57.210^*	< 0.001^*
Median (Min.–Max.)	17.5 (15–20)	16 (12–20)	10 (6–16)	11 (7–15)	57.210^*	< 0.001^*
p₁		0.016^*	< 0.001^*	< 0.001^*

SD: standard deviation
F: F test (ANOVA) with repeated measures, Sig. bet. periods was done using post hoc test (adjusted Bonferroni)
p: p value for comparing between the different studied periods
p₁: p value for comparing between PSQI 0 and each other period in each group
^*Statistically significant at p ≤ 0.05